Document is current

Any future updates will be listed below

Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways

Crossref DOI link: https://doi.org/10.1007/s00109-016-1430-3

Published Online: 2016-06-24

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark